TABLE 3.
Association of miRNAs expression levels with clinico-pathological factors of colorectal cancer patients (presented as mean ± SD).
| Variable | N | MiR-96 | p value | MiR-99b | p value | MiR-155 | p value | Let-7a | p value | Let-7b | p value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | — | — | 0.34 | — | 0.82 | — | 0.40 | — | 0.46 | — | 0.39 |
| Male | 55 | 4.88 ± 1.25 | — | 0.52 ± 0.27 | — | 2.71 ± 1.24 | — | 2.63 ± 1.03 | — | 0.44 ± 0.29 | — |
| Female | 35 | 5.16 ± 1.41 | — | 0.51 ± 0.34 | — | 2.92 ± 1.09 | — | 2.78 ± 0.86 | — | 0.51 ± 0.42 | — |
| Age | — | — | 0.39 | — | 0.24 | — | 0.92 | — | 0.62 | — | 0.83 |
| <60 | 50 | 5.10 ± 1.36 | — | 0.49 ± 0.28 | — | 2.78 ± 1.11 | — | 2.73 ± 0.95 | — | 0.46 ± 0.33 | — |
| ≥60 | 40 | 4.85 ± 1.23 | — | 0.56 ± 0.32 | — | 2.807 ± 1.30 | — | 2.63 ± 0.99 | — | 0.48 ± 0.38 | — |
| Degree differentiation | — | — | 0.48 | — | 0.78 | — | 0.17 | — | 0.66 | — | 0.07 |
| Poor | 256 | 4.83 ± 1.19 | — | 0.51 ± 0.27 | — | 3.07 ± 1.25 | — | 2.61 ± 0.86 | — | 0.38 ± 0.22 | — |
| Well | 65 | 5.05 ± 1.35 | — | 0.53 ± 0.31 | — | 2.68 ± 1.16 | — | 2.71 ± 1.01 | — | 0.50 ± 0.38 | — |
| Tumor diameter (cm) | — | — | 0.22 | — | 0.31 | — | 0.15 | — | 0.50 | — | 0.76 |
| <5 | 54 | 4.85 ± 1.17 | — | 0.55 ± 0.31 | — | 2.64 ± 1.19 | — | 2.63 ± 0.94 | — | 0.48 ± 0.35 | — |
| ≥5 | 36 | 5.20 ± 1.89 | — | 0.48 ± 0.27 | — | 3.01 ± 1.18 | — | 2.77 ± 1.01 | — | 0.45 ± 0.34 | — |
| T stage | — | — | 0.01 | — | 0.02 | 0.03 | — | 0.004 | — | 0.001 | |
| Tis-T2 | 11 | 3.99 ± 1.16 | — | 0.78 ± 0.36 | — | 1.81 ± 0.36 | — | 1.79 ± 0.89 | — | 0.79 ± 0.59 | — |
| T3-T4 | 79 | 5.13 ± 1.27 | — | 0.49 ± 0.27 | — | 2.93 ± 1.11 | — | 2.81 ± 0.91 | — | 0.42 ± 0.27 | — |
| N stage | — | — | 0.00 | — | 0.00 | — | 0.00 | — | 0.001* | — | 0.00 |
| N0 | 22 | 3.89 ± 1.09 | — | 0.84 ± 0.29 | — | 1.69 ± 0.80 | — | 1.71 ± 0.83 | — | 0.81 ± 0.42 | — |
| N1+N2 | 68 | 5.34 ± 1.17 | — | 0.42 ± 0.22 | — | 3.15 ± 1.07 | — | 2.99 ± 0.78 | — | 0.36 ± 0.24 | — |
| M stage | — | — | 0.00 | — | 0.00 | — | 0.00 | — | 0.001* | — | 0.00 |
| Absent | 41 | 4.08 ± 1.11 | — | 0.76 ± 0.27 | — | 2.13 ± 0.93 | — | 2.08 ± 0.84 | — | 0.62 ± 0.38 | — |
| Present | 49 | 5.75 ± 0.92 | — | 0.32 ± 0.12 | — | 3.35 ± 1.09 | — | 3.19 ± 0.76 | — | 0.34 ± 0.25 | — |
| Clinical stage | — | — | 0.00 | — | 0.00 | — | 0.00 | — | 0.001* | — | 0.00 |
| Early (I-II) | 20 | 3.71 ± 0.95 | — | 0.91 ± 0.21 | — | 1.53 ± 0.50 | — | 1.53 ± 0.58 | — | 0.85 ± 0.41 | — |
| Advanced (III-IV) | 70 | 5.35 ± 1.16 | — | 0.41 ± 0.22 | — | 3.15 ± 1.08 | — | 3.01 ± 0.78 | — | 0.36 ± 0.23 | — |
| CEA | — | — | 0.03 | — | 0.01 | — | 1.13 | — | 0.09 | — | 0.05 |
| <5 ng\L | 42 | 4.66 ± 1.27 | — | 0.60 ± 0.20 | — | 2.59 ± 1.15 | — | 2.51 ± 0.88 | — | 0.55 ± 0.36 | — |
| ≥5 ng\L | 48 | 5.28 ± 1.29 | — | 0.45 ± 0.29 | — | 2.97 ± 1.21 | — | 2.84 ± 1.02 | — | 0.40 ± 0.32 | — |
Note: Independent-samples t test was conducted.